Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 9Not yet recruiting 3Withdrawn 2Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Gastrointestinal 1CNS 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1Bile Duct Neoplasms 1

Interventions

Cyclophosphamide 1492Cisplatin 1413Paclitaxel 1316Radiotherapy 1261Carboplatin 1249Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700Etoposide 678pembrolizumab 677Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 419

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Interventional × olutasidenib × Clear all
NCT02719574 2025-06-26

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
336 enrolled 48 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03684811 2023-11-18

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Novo Nordisk A/S

Phase 1/2 Completed
93 enrolled 24 charts
CNSGastrointestinal

Bile Duct Neoplasms, Glioblastoma, Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡